within Pharmacolibrary.Drugs.ATC.L;

model L04AJ04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 6100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0056,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0026,
    k12             = 0.378,
    k21             = 0.378
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AJ04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sutimlimab is a humanized monoclonal antibody that inhibits complement component C1s. It is used primarily in the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. Sutimlimab is approved for use in adults with CAD to prevent hemolysis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients (majority female, mean age ~70 years) with cold agglutinin disease after intravenous administration.</p><h4>References</h4><ol><li><p>Bartko, J, et al., &amp; Jilma, B (2018). A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway. <i>Clinical pharmacology and therapeutics</i> 104(4) 655–663. DOI:<a href=\"https://doi.org/10.1002/cpt.1111\">10.1002/cpt.1111</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29737533/\">https://pubmed.ncbi.nlm.nih.gov/29737533</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AJ04;
